JCR Pharmaceuticals (4552) · InitiativeRestated
Acquisition of Blood-Brain Barrier Penetration Technology and Intellectual Property Rights Through the Acquisition of ArmaGen
First written in FY2020. 1 of 2 entries say "Restated". Latest entry: FY2021-Q1.
2entries
1years
0from disclosures
How it moved
Same theme, other companies
Acquisition of blood-brain barrier penetration technology and intellectual property through the acquisition of ArmaGenA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2021-Q1RestatedAnnual report
「At a meeting of the Board of Directors held on 27 February 2020, we resolved to acquire ArmaGen, Inc., and completed the acquisition on 10 April of the same year. The acquisition was undertaken to secure our technological advantage by acquiring technology assets, including intellectual property relating to ArmaGen’s blood-brain barrier (hereinafter, BBB) penetration technology, and was accounted for as an asset acquisition.」
The company reconfirmed completion of the acquisition of ArmaGen on 10 April 2020 and its inclusion in the scope of consolidation. Acquired patent rights amounted to ¥3,287 million, the weighted-average amortisation period was 11.88 years, and the post-acquisition ownership interest was 100%. - FY2020First statedAnnual report
「At a meeting of the Board of Directors held on 27 February 2020, we resolved to make ArmaGen, Inc. a subsidiary, and completed the transaction on 10 April of the same year.」
On 10 April 2020, after the filing date, the company completed the acquisition of ArmaGen’s shares and made it a wholly owned subsidiary. The purpose was to acquire its technology assets, including intellectual property relating to blood-brain barrier-penetration technology in the United States and elsewhere.